Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections
European Journal of Clinical Pharmacology · 2024-11 · 80 (11) · 1829-1840
DOI: 10.1007/s00228-024-03752-z ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 06.09.2024. Verfasst von Matylda Resztak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland. mresztak@ump.edu.pl. Hauptthemen laut MEDLINE: Voriconazole, Cytochrome P-450 CYP2C19, Drug Monitoring, Antifungal Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Therapeutic drug monitoring (TDM) of voriconazole (VCZ) should be mandatory for all pediatric patients with invasive fungal infections (IFIs). The narrow therapeutic index, inter-individual variability in VCZ pharmacokinetics, and genetic polymorphisms cause achieving therapeutic concentration during therapy to be challenging in this population.
Methods
The study included 44 children suffering from IFIs treated with VCZ. Trough concentrations (C trough ) of VCZ ware determined by the HPLC-FLD method. Identification of the CYP2C19*2 and CYP2C19*17 genetic polymorphisms was performed by PCR–RFLP. The correlation between polymorphisms and VCZ C trough was analyzed. Moreover, the effect of factors such as dose, age, sex, route of administration, and drug interactions was investigated.
Results
VCZ was administered orally and intravenously at a median maintenance dosage of 14.7 mg/kg/day for a median of 10 days. The VCZ C trough was highly variable and ranged from 0.1 to 6.8 mg/L. Only 45% of children reached the therapeutic range. There was no significant association between C trough and dosage, age, sex, route of administration, and concomitant medications. The frequencies of variant phenotype normal (NM), intermediate (IM), rapid (RM) and ultrarapid metabolizers (UM) were 41%, 18%, 28%, and 13%, respectively. C trough of VCZ were significantly higher in NM and IM groups compared with RM, and UM groups.
Conclusion
The C trough of VCZ is characterized by inter-individual variability and a low rate of patients reaching the therapeutic range. The significant association exists in children between VCZ C trough and CYPC19 phenotype. The combination of repeated TDM and genotyping is necessary to ensure effective treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland. mresztak@ump.edu.pl.
- Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznań, Poland.
- Department of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Poznań, Poland.
Zitieren
APA
Resztak, M., Zalewska, P., Wachowiak, J., Sobkowiak-Sobierajska, A., & Główka, F. K. (2024). Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections. European Journal of Clinical Pharmacology, 80(11), 1829-1840. https://doi.org/10.1007/s00228-024-03752-z
Vancouver
Resztak M, Zalewska P, Wachowiak J, Sobkowiak-Sobierajska A, Główka FK. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections. European Journal of Clinical Pharmacology. 2024;80(11):1829-1840. doi:10.1007/s00228-024-03752-z
BibTeX
@article{Resztak2024,
author = {Resztak, Matylda and Zalewska, Paulina and Wachowiak, Jacek and Sobkowiak-Sobierajska, Agnieszka and Główka, Franciszek K},
title = {Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
volume = {80},
number = {11},
pages = {1829--1840},
doi = {10.1007/s00228-024-03752-z}
}
EUVIMED